- Home
- NCPL vs IBO Comparison
NCPL vs IBO Comparison
Compare NCPL & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- IBO
- Stock Information
- Founded
- NCPL 1984
- IBO 2018
- Country
- NCPL United States
- IBO United States
- Employees
- NCPL N/A
- IBO N/A
- Industry
- NCPL Investment Managers
- IBO
- Sector
- NCPL Finance
- IBO
- Exchange
- NCPL Nasdaq
- IBO NYSE
- Market Cap
- NCPL 4.3M
- IBO 5.1M
- IPO Year
- NCPL N/A
- IBO 2024
- Fundamental
- Price
- NCPL $2.70
- IBO $0.51
- Analyst Decision
- NCPL
- IBO
- Analyst Count
- NCPL 0
- IBO 0
- Target Price
- NCPL N/A
- IBO N/A
- AVG Volume (30 Days)
- NCPL 166.3K
- IBO 936.6K
- Earning Date
- NCPL 07-28-2025
- IBO 06-13-2025
- Dividend Yield
- NCPL N/A
- IBO N/A
- EPS Growth
- NCPL N/A
- IBO N/A
- EPS
- NCPL N/A
- IBO N/A
- Revenue
- NCPL $812,612.00
- IBO N/A
- Revenue This Year
- NCPL N/A
- IBO N/A
- Revenue Next Year
- NCPL $101.16
- IBO N/A
- P/E Ratio
- NCPL N/A
- IBO N/A
- Revenue Growth
- NCPL N/A
- IBO N/A
- 52 Week Low
- NCPL $1.41
- IBO $0.37
- 52 Week High
- NCPL $11.90
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- NCPL 76.49
- IBO N/A
- Support Level
- NCPL $1.75
- IBO N/A
- Resistance Level
- NCPL $2.19
- IBO N/A
- Average True Range (ATR)
- NCPL 0.21
- IBO 0.00
- MACD
- NCPL 0.07
- IBO 0.00
- Stochastic Oscillator
- NCPL 84.85
- IBO 0.00
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.